Korean journal of dermatology (대한피부과학회지)

Korean Dermatological Association (대한피부과학회)
권호 표지

Treatment of Atopic Dermatitis

아토피피부염의 치료

  • Han, Tae-Young (Department of Dermatology, College of Medicine, Eulji University) ;
  • Na, Chan Ho (Department of Dermatology, College of Medicine, Chosun University) ;
  • Lee, Ji Hyun (Department of Dermatology, College of Medicine, The Catholic University of Korea) ;
  • Kim, Hye One (Department of Dermatology, College of Medicine, Hallym University) ;
  • Park, Chang Ook (Department of Dermatology, College of Medicine, Yonsei University) ;
  • Seo, Young Joon (Department of Dermatology, College of Medicine, Chungnam University) ;
  • Son, Sang Wook (Department of Dermatology, College of Medicine, Korea University) ;
  • Shin, Min Kyung (Department of Dermatology, College of Medicine, Kyunghee University) ;
  • Ahn, Ji Young (Department of Dermatology, National Medical Center) ;
  • Lee, Yang Won (Department of Dermatology, Konkuk University School of Medicine) ;
  • Jang, Yong Hyun (Department of Dermatology, School of Medicine, Kyungpook National University) ;
  • Park, Young Lip (Department of Dermatology, College of Medicine, Soonchunhyang University) ;
  • Lew, Bark Lynn (Department of Dermatology, College of Medicine, Kyunghee University)
  • 한태영 (을지대학교 의과대학 피부과학교실) ;
  • 나찬호 (조선대학교 의과대학 피부과학교실) ;
  • 이지현 (가톨릭대학교 의과대학 피부과학교실) ;
  • 김혜원 (한림대학교 의과대학 피부과학교실) ;
  • 박창욱 (연세대학교 의과대학 피부과학교실) ;
  • 서영준 (충남대학교 의과대학 피부과학교실) ;
  • 손상욱 (고려대학교 의과대학 피부과학교실) ;
  • 신민경 (경희대학교 의과대학 피부과학교실) ;
  • 안지영 (국립중앙의료원 피부과) ;
  • 이양원 (건국대학교 의과대학 피부과학교실) ;
  • 장용현 (경북대학교 의과대학 피부과학교실) ;
  • 박영립 (순천향대학교 의과대학 피부과학교실) ;
  • 유박린 (경희대학교 의과대학 피부과학교실)
  • Received : 2018.11.26
  • Accepted : 2018.12.03
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Atopic dermatitis (AD) is a common, chronic, relapsing, inflammatory skin disease that affects both children and adults. AD is the cause of considerable morbidity including severe pruritus and impaired quality of life. Treatments for active disease include avoidance of triggering factors, barrier repair, topical medications including topical corticosteroids (TCs) and topical calcineurin inhibitors (TCIs), phototherapy, antibacterial agents, and systemic immunosuppressants including cyclosporine. Until recently, the only Food and Drug Administration (FDA)-approved systemic treatment options for patients with moderate-to-severe AD were steroids and cyclosporine. Systemic steroids are not recommended by current guidelines and are commonly associated with disease rebound. Instead, clinicians choose from several off-label immunosuppressants. In 2018, the Korean FDA approved dupilumab for adults with moderate-to-severe AD whose disease is not adequately controlled with topical therapies. The implementation of treatment guidelines for AD is challenging. Herein, we review the several treatment modalities for AD and recommend a treatment algorithm.

Keywords

Acknowledgement

Supported by : 대한아토피피부염학회

References

  1. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. J Invest Dermatol 2011;131:67-73 https://doi.org/10.1038/jid.2010.251
  2. Drucker AM. Atopic dermatitis: burden of illness, quality of life, and associated complications. Allergy Asthma Proc 2017;38:3-8
  3. Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol 2018;120:10-22 https://doi.org/10.1016/j.anai.2017.10.039
  4. Silverberg JI. Healthcare utilization, patient costs, and access to care in US adults with eczema: a population-based study. JAMA Dermatol 2015;151:743-752 https://doi.org/10.1001/jamadermatol.2014.5432
  5. Lee SH, Lee SH, Lee SY, Lee B, Lee S-H, Park YL. Psychological health status and health-related quality of life in adults with atopic dermatitis: A nationwide crosssectional study in South Korea. Acta Derm Venereol 2018;98:89-97 https://doi.org/10.2340/00015555-2797
  6. Elias PM, Eichenfield LF, Fowler J, Horowitz P, McLeod RP. Update on the structure and function of the skin barrier: atopic dermatitis as an exemplar of clinical implications. Semin Cutan Med Surg 2013;32:S21-S24 https://doi.org/10.12788/j.sder.0022
  7. Simpson E, Trookman NS, Rizer RL, Preston N, Colon LE, Johnson LA, et al. Safety and tolerability of a body wash and moisturizer when applied to infants and toddlers with a history of atopic dermatitis: results from an open-label study. Pediatr Dermatol 2012;29:590-597 https://doi.org/10.1111/j.1525-1470.2012.01809.x
  8. Kim JE, Kim HJ, Lew B-L, Lee KH, Hong SP, Jang YH, et al. Consensus guidelines for the treatment of atopic dermatitis in Korea (part I): general management and topical treatment. Ann Dermatol 2015;27:563-577 https://doi.org/10.5021/ad.2015.27.5.563
  9. Sakai T, Hatano Y, Zhang W, Fujiwara S. Defective maintenance of pH of stratum corneum is correlated with preferential emergence and exacerbation of atopic-dermatitis-like dermatitis in flaky-tail mice. J Dermatol Sci 2014;74:222-228 https://doi.org/10.1016/j.jdermsci.2014.01.012
  10. Lee HJ, Lee SH. Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis. Allergy Asthma Immunol Res 2014;6:276-287 https://doi.org/10.4168/aair.2014.6.4.276
  11. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 2018;32:657-682 https://doi.org/10.1111/jdv.14891
  12. Katayama I, Kohno Y, Akiyama K, Aihara M, Kondo N, Saeki H, et al. Japanese guideline for atopic dermatitis 2014. Allergol Int 2014;63:377-398 https://doi.org/10.2332/allergolint.14-RAI-0769
  13. Jeong KY, Park JW, Hong CS. House dust mite allergy in Korea: the most important inhalant allergen in current and future. Allergy Asthma Immunol Res 2012;4:313-325 https://doi.org/10.4168/aair.2012.4.6.313
  14. Lopes C, Silva D, Delgado L, Correia O, Moreira A. Functional textiles for atopic dermatitis: a systematic review and meta-analysis. Pediatr Allergy Immunol 2013;24:603-613 https://doi.org/10.1111/pai.12111
  15. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012;26:1045-1060 https://doi.org/10.1111/j.1468-3083.2012.04635.x
  16. Barbarot S, Bernier C, Deleuran M, De Raeve L, Eichenfield L, El Hachem M, et al. Therapeutic patient education in children with atopic dermatitis: position paper on objectives and recommendations. Pediatr Dermatol 2013;30:199-206 https://doi.org/10.1111/pde.12045
  17. Boralevi F, Saint Aroman M, Delarue A, Raudsepp H, Kaszuba A, Bylaite M, et al. Long-term emollient therapy improves xerosis in children with atopic dermatitis. J Eur Acad Dermatol Venereol 2014;28:1456-1462 https://doi.org/10.1111/jdv.12314
  18. Sher LG, Chang J, Patel IB, Balkrishnan R, Fleischer Jra AB. Relieving the pruritus of atopic dermatitis: a meta-analysis. Acta Derm Venereol 2012;92:455-461 https://doi.org/10.2340/00015555-1360
  19. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002;147:528-537 https://doi.org/10.1046/j.1365-2133.2002.05006.x
  20. Nilsson EJ, Henning CG, Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol 1992;27:29-34 https://doi.org/10.1016/0190-9622(92)70151-5
  21. Ference JD, Last AR. Choosing topical corticosteroids. Am Fam Physician 2009;79:135-140
  22. Dekio I, Morita E. The weight of a finger-tip unit of ointment in 5-gram tubes. J Dermatolog Treat 2011;22:302-303 https://doi.org/10.3109/09546631003797098
  23. Berth-Jones J, Damstra RJ, Golsch S, Livden JK, Van Hooteghem O, Allegra F, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. Bmj 2003;326:1367 https://doi.org/10.1136/bmj.326.7403.1367
  24. Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 2011;164:415-428 https://doi.org/10.1111/j.1365-2133.2010.10030.x
  25. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006;54:1-15; quiz 16-18 https://doi.org/10.1016/j.jaad.2005.01.010
  26. Janmohamed SR, Oranje AP, Devillers AC, Rizopoulos D, van Praag MC, Van Gysel D, et al. The proactive wet-wrap method with diluted corticosteroids versus emollients in children with atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2014;70:1076-1082 https://doi.org/10.1016/j.jaad.2014.01.898
  27. Albarran-Planelles C, Jimenez-Gallo D, Linares-Barrios M, Martinez-Rodriguez A. Our experience with wet-wrap treatment. Actas Dermosifiliogr 2014;105:e18-21 https://doi.org/10.1016/j.ad.2013.11.004
  28. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014;71:116-132 https://doi.org/10.1016/j.jaad.2014.03.023
  29. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: metaanalysis of randomised controlled trials. Bmj 2005;330:516 https://doi.org/10.1136/bmj.38376.439653.D3
  30. Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatolog Treat 2010;21:144-156 https://doi.org/10.3109/09546630903401470
  31. Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev 2015:Cd009864
  32. Reitamo S, Rustin M, Harper J, Kalimo K, Rubins A, Cambazard F, et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol 2008;159:942-951 https://doi.org/10.1111/j.1365-2133.2008.08747.x
  33. Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar ML, Zhu X, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics 2015;135:597-606 https://doi.org/10.1542/peds.2014-1990
  34. Van Leent EJ, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD. Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology 2002;204:63-68
  35. Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007;214:289-295 https://doi.org/10.1159/000100879
  36. Margolis DJ, Abuabara K, Hoffstad OJ, Wan J, Raimondo D, Bilker WB. Association Between Malignancy and Topical Use of Pimecrolimus. JAMA Dermatol 2015;151:594-599 https://doi.org/10.1001/jamadermatol.2014.4305
  37. Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 2016;75:494-503.e496 https://doi.org/10.1016/j.jaad.2016.05.046
  38. Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. Journal of the American Academy of Dermatology 2014;71:327-349 https://doi.org/10.1016/j.jaad.2014.03.030
  39. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. British Journal of Dermatology 2003;148:1212-1221 https://doi.org/10.1046/j.1365-2133.2003.05293.x
  40. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018;32:850-878 https://doi.org/10.1111/jdv.14888
  41. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol 2012;26:1176-1193 https://doi.org/10.1111/j.1468-3083.2012.04636.x
  42. Boguniewicz M, Sampson H, Leung SB, Harbeck R, Leung DY. Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. Journal of Allergy and Clinical Immunology 2001;108:651-652 https://doi.org/10.1067/mai.2001.118598
  43. Kim JE, Kim HJ, Lew B-L, Lee KH, Hong SP, Jang YH, et al. Consensus guidelines for the treatment of atopic dermatitis in Korea (part II): systemic treatment. Annals of dermatology 2015;27:578-592 https://doi.org/10.5021/ad.2015.27.5.578
  44. Mayser P, Kupfer J, Nemetz D, Schafer U, Nilles M, Hort W, et al. Treatment of head and neck dermatitis with ciclopiroxolamine cream-results of a double-blind, placebo-controlled study. Skin pharmacology and physiology 2006;19:153-158 https://doi.org/10.1159/000092596
  45. Lintu P, Savolainen J, Kortekangas-Savolainen O, Kalimo K. Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeasts. Allergy 2001;56:512-517 https://doi.org/10.1034/j.1398-9995.2001.056006512.x
  46. Forte WN, Sumita JM, Rodrigues AG, Liuson D, Tanaka E. Rebound phenomenon to systemic corticosteroid in atopic dermatitis. Allergologia et immunopathologia 2005;33:307-311 https://doi.org/10.1016/S0301-0546(05)73248-1
  47. Schmitt J, Schakel K, Folster-Holst R, Bauer A, Oertel R, Augustin M, et al. Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebocontrolled multicentre trial. British Journal of Dermatology 2010;162:661-668 https://doi.org/10.1111/j.1365-2133.2009.09561.x
  48. Daley-Yates PT, Richards DH. Relationship between systemic corticosteroid exposureand growth velocity: development and validation of a pharmacokinetic/pharmacodynamic model. Clinical therapeutics 2004;26:1905-1919 https://doi.org/10.1016/j.clinthera.2004.11.017
  49. Czech W, Brautigam M, Weidinger G, Schopf E. A bodyweight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. Journal of the American Academy of Dermatology 2000;42:653-659
  50. El-Khalawany MA, Hassan H, Shaaban D, Ghonaim N, Eassa B. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. European journal of pediatrics 2013;172:351-356 https://doi.org/10.1007/s00431-012-1893-3
  51. Berth-Jones J, Finlay AY, Zaki I, Tan B, Goodyear H, Lewis-Jones S, et al. Cyclosporine in severe childhood atopic dermatitis: a multicenter study. Journal of the American Academy of Dermatology 1996;34:1016-1021 https://doi.org/10.1016/S0190-9622(96)90281-9
  52. Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. British Journal of Dermatology 2002;147:324-330 https://doi.org/10.1046/j.1365-2133.2002.04989.x
  53. Caufield M, Tom WL. Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring. Journal of the American Academy of Dermatology 2013;68:29-35 https://doi.org/10.1016/j.jaad.2012.07.001
  54. Schram ME, Roekevisch E, Leeflang MMG, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. Journal of Allergy and Clinical Immunology 2011;128:353-359 https://doi.org/10.1016/j.jaci.2011.03.024
  55. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. The Lancet 2006;367:839-846 https://doi.org/10.1016/S0140-6736(06)68340-2
  56. Ballester I, Silvestre J, Perez-Crespo M, Lucas A. Severe adult atopic dermatitis: treatment with mycophenolate mofetil in 8 patients. Actas Dermo-Sifiliograficas (English Edition) 2009;100:883-887 https://doi.org/10.1016/S1578-2190(09)70559-1
  57. Haeck IM, Knol MJ, ten Berge O, van Velsen SG, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. Journal of the American Academy of Dermatology 2011;64:1074-1084 https://doi.org/10.1016/j.jaad.2010.04.027
  58. Heller M, Shin H, Orlow S, Schaffer J. Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. British Journal of Dermatology 2007;157:127-132 https://doi.org/10.1111/j.1365-2133.2007.07947.x
  59. D'erme AM, Milanesi N, Agnoletti AF, Maio V, Massi D, Gola M. Efficacy of treatment with oral alitretinoin in patient suffering from lichen simplex chronicus and severe atopic dermatitis of hands. Dermatologic therapy 2014;27:21-23 https://doi.org/10.1111/dth.12035
  60. Broshtilova V, Gantcheva M. Therapeutic Hotline: Cysteinyl leukotriene receptor antagonist montelukast in the treatment of atopic dermatitis. Dermatol Ther 2010;23:90-93 https://doi.org/10.1111/j.1529-8019.2009.01295.x
  61. Holme H, Winckworth LC. Montelukast can reduce the severity and extent of atopic dermatitis. J Paediatr Child Health 2013;49:412-415 https://doi.org/10.1111/jpc.12202
  62. Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol 2014;133:429-438 https://doi.org/10.1016/j.jaci.2013.07.049
  63. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. Journal of Allergy and Clinical Immunology 2011;127:S1-S55 https://doi.org/10.1016/j.jaci.2010.09.034
  64. Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. Journal of Allergy and Clinical Immunology 2013;132:110-117 https://doi.org/10.1016/j.jaci.2013.02.044
  65. Bussmann C, Bockenhoff A, Henke H, Werfel T, Novak N. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? Journal of allergy and clinical immunology 2006;118:1292-1298 https://doi.org/10.1016/j.jaci.2006.07.054
  66. Tintle S, Shemer A, Suarez-Farinas M, Fujita H, Gilleaudeau P, Sullivan-Whalen M, et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. Journal of Allergy and Clinical Immunology 2011;128:583-593. e584 https://doi.org/10.1016/j.jaci.2011.05.042
  67. Gambichler T, Terras S, Kreuter A. Treatment regimens, protocols, dosage, and indications for UVA1 phototherapy: facts and controversies. Clinics in dermatology 2013;31:438-454 https://doi.org/10.1016/j.clindermatol.2013.01.011
  68. Grundmann SA, Beissert S. Modern aspects of phototherapy for atopic dermatitis. J Allergy (Cairo) 2012;2012:121797
  69. Tay YK, Morelli JG, Weston WL. Experience with UVB phototherapy in children. Pediatr Dermatol 1996;13:406-409 https://doi.org/10.1111/j.1525-1470.1996.tb00711.x
  70. Werfel T. Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 2017/2018. Curr Opin Allergy Clin Immunol 2018;18:432-437 https://doi.org/10.1097/ACI.0000000000000477
  71. Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014;371:130-139 https://doi.org/10.1056/NEJMoa1314768
  72. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med 2016;375:2335-2348 https://doi.org/10.1056/NEJMoa1610020
  73. Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol 2018;78:S28-S36 https://doi.org/10.1016/j.jaad.2017.12.022
  74. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017;389:2287-2303 https://doi.org/10.1016/S0140-6736(17)31191-1
  75. de Bruin-Weller M, Thaci D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol 2018;178:1083-1101 https://doi.org/10.1111/bjd.16156
  76. Han Y, Chen Y, Liu X, Zhang J, Su H, Wen H, et al. Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol 2017;140:888-891e886 https://doi.org/10.1016/j.jaci.2017.04.015
  77. Wang FP, Tang XJ, Wei CQ, Xu LR, Mao H, Luo FM. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. J Dermatol Sci 2018;90:190-198 https://doi.org/10.1016/j.jdermsci.2018.01.016
  78. Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005;60:693-696 https://doi.org/10.1111/j.1398-9995.2005.00791.x
  79. Khattri S, Brunner PM, Garcet S, Finney R, Cohen SR, Oliva M, et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp Dermatol 2017;26:28-35 https://doi.org/10.1111/exd.13112
  80. Saeki H, Kabashima K, Tokura Y, Murata Y, Shiraishi A, Tamamura R, et al. Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study. Br J Dermatol 2017;177:419-427 https://doi.org/10.1111/bjd.15493
  81. Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, et al. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. N Engl J Med 2017;376:826-835 https://doi.org/10.1056/NEJMoa1606490
  82. Simon D, Hosli S, Kostylina G, Yawalkar N, Simon HU. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008;121:122-128 https://doi.org/10.1016/j.jaci.2007.11.016
  83. Sediva A, Kayserova J, Vernerova E, Polouckova A, Capkova S, Spisek R, et al. Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol 2008; 121:1515-1516; author reply 1516-1517 https://doi.org/10.1016/j.jaci.2008.03.007
  84. Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 2010;8:990-998
  85. Hotze M, Baurecht H, Rodriguez E, Chapman-Rothe N, Ollert M, Folster-Holst R, et al. Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy 2014;69:132-135 https://doi.org/10.1111/all.12234
  86. Lacombe Barrios J, Begin P, Paradis L, Hatami A, Paradis J, Des Roches A. Anti-IgE therapy and severe atopic dermatitis: a pediatric perspective. J Am Acad Dermatol 2013;69:832-834 https://doi.org/10.1016/j.jaad.2013.05.035
  87. Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT, et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol 2013;162:89-93 https://doi.org/10.1159/000350486
  88. Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol 2016;138:336-349 https://doi.org/10.1016/j.jaci.2016.06.010
  89. Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taieb A, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol 2018;78:863-871 e811 https://doi.org/10.1016/j.jaad.2018.01.017
  90. Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol 2018
  91. Peng W, Novak N. Recent developments in atopic dermatitis. Curr Opin Allergy Clin Immunol 2014;14:417-422 https://doi.org/10.1097/ACI.0000000000000094
  92. Guttman-Yassky E, Brunner PM, Neumann AU, Khattri S, Pavel AB, Malik K, et al. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. J Am Acad Dermatol 2018;78:872-881 e876 https://doi.org/10.1016/j.jaad.2018.01.016
  93. Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple- dose study. J Am Acad Dermatol 2018
  94. Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol 2015;73:395-399 https://doi.org/10.1016/j.jaad.2015.06.045
  95. Samrao A, Berry TM, Goreshi R, Simpson EL. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol 2012;148:890-897
  96. Kim SO, Ah YM, Yu YM, Choi KH, Shin WG, Lee JY. Effects of probiotics for the treatment of atopic dermatitis: a meta-analysis of randomized controlled trials. Ann Allergy Asthma Immunol 2014;113:217-226 https://doi.org/10.1016/j.anai.2014.05.021
  97. Panduru M, Panduru NM, Salavastru CM, Tiplica GS. Probiotics and primary prevention of atopic dermatitis: a meta-analysis of randomized controlled studies. J Eur Acad Dermatol Venereol 2015;29:232-242 https://doi.org/10.1111/jdv.12496
  98. Morse NL, Clough PM. A meta-analysis of randomized, placebo-controlled clinical trials of Efamol evening primrose oil in atopic eczema. Where do we go from here in light of more recent discoveries? Curr Pharm Biotechnol 2006;7:503-524 https://doi.org/10.2174/138920106779116946
  99. Bamford JT, Ray S, Musekiwa A, van Gool C, Humphreys R, Ernst E. Oral evening primrose oil and borage oil for eczema. Cochrane Database Syst Rev 2013:CD004416
  100. Camargo CA, Jr., Ganmaa D, Sidbury R, Erdenedelger K, Radnaakhand N, Khandsuren B. Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children. J Allergy Clin Immunol 2014;134:831-835 e831 https://doi.org/10.1016/j.jaci.2014.08.002
  101. Peroni DG, Piacentini GL, Cametti E, Chinellato I, Boner AL. Correlation between serum 25-hydroxyvitamin D levels and severity of atopic dermatitis in children. Br J Dermatol 2011;164:1078-1082 https://doi.org/10.1111/j.1365-2133.2010.10147.x
  102. Chiu YE, Havens PL, Siegel DH, Ali O, Wang T, Holland KE, et al. Serum 25-hydroxyvitamin D concentration does not correlate with atopic dermatitis severity. J Am Acad Dermatol 2013;69:40-46 https://doi.org/10.1016/j.jaad.2013.01.010